TXNRD1 and cancer: TrxR1 (EC 1.8.1.9), a mammalian cytosolic isoform, is overexpressed in many cancers, so it can be considered an attractive approach and a valuable target for the development of anticancer drugs (Fan et al. 2014; Zhang et al. 2017; Rajavel et al. 2019; Jovanović et al. 2020).